RxDoctor Payments DataLook up a doctor →

Viral Doshi, MD

Sleep Medicine · Oklahoma City, OKNPI 1164654117

Payments from drug & device makers

$55,685in general payments, 2019–2025

Across 835 payments — averaging $66.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$20K
  • Mylan Specialty L.p.$18K
  • Inspire Medical Systems, Inc.$3K
  • AstraZeneca$3K
  • Harmony Biosciences LLC$2K
  • GSK$2K
  • plus $7K from 45 others

What the payments were for

  • Consulting fees$5,38910%
  • Speaking & faculty fees$29,31953%
  • Travel & lodging$5,30510%
  • Food & beverage$15,23327%
  • Education$4391%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$55,685 in reported general payments places this provider in the 85th percentile of 20 sleep medicine providers in Oklahoma.

See all sleep medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$175,788
Medicare patients
1,191
Services billed
1,747

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter384$302,477
LumryzSodium Oxybate15$107,331
Fasenra PenBenralizumab13$79,886
BelsomraSuvorexant128$58,750
Breo ElliptaFluticasone/Vilanterol105$55,813
Breztri AerosphereBudesonide/Glycopyr/Formoterol70$47,562
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr82$46,243
Dupixent PenDupilumab11$40,686
SunosiSolriamfetol Hcl15$21,436
Advair HfaFluticasone Propion/Salmeterol31$18,571
Spiriva RespimatTiotropium Bromide32$16,805
SymbicortBudesonide/Formoterol Fumarate56$16,402
Stiolto RespimatTiotropium Br/Olodaterol Hcl21$9,434
Fluticasone-SalmeterolFluticasone Propion/Salmeterol69$8,170
Incruse ElliptaUmeclidinium Bromide15$5,109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$1,833$409,643586 claims
Avadel CNS Pharmaceuticals, LLCLumryz$453$107,33115 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,769$63,965126 claims
MerckBelsomra$301$58,750128 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$1,157$26,23953 claims
Axsome Therapeutics, Inc.Sunosi$381$21,43615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 20 sleep medicine providers in Oklahoma.

Other sleep medicine in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →